OBJECTIVE Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in children. The aim of this study was to investigate the associations of oxidative stress with insulin resistance and metabolic risk factors in obese adolescents with NAFLD. METHODS Forty-six obese adolescents (23 girls and 23 boys, mean age: 12.8 ± 2.2 years) and 29 control subjects ...

Objectives: The present study was undertaken to explore whether MetS and its individual components are associated with NAFLD. Materials and methods: 67 diagnosed NAFLD subjects and 50 healthy controls were included. NAFLD was diagnosed by ultrasound and serum C-peptide was measured by Immulite technique. Results: The NAFLD and control subjects were age and BMImatched (age in years, p=0.380 and ...

Pediatric obesity has increased dramatically all over the world and nonalcoholic fatty liver disease (NAFLD) is one of the most frequent complications associated with excess adiposity. NAFLD causes serum transaminase elevation and liver disease, which could end up in fibrosis, cirrhosis and eventually hepatocellular carcinoma. NAFLD seems to be associated with the metabolic complications of obe...

BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease worldwide with tremendous clinical burden. The economic burden of NAFLD is not well studied. GOAL To assess the economic burden of NAFLD. STUDY Medicare beneficiaries (January 1, 2010 to December 31, 2010) with NAFLD diagnosis by International Classification of Diseases, Ninth Revision ...

Intestinal FGF19 has emerged as a novel endocrine regulator of hepatic bile salt and lipid metabolism. In patients with nonalcoholic fatty liver disease (NAFLD) hepatic lipid metabolism is deranged. A possible role of FGF19 in NAFLD has not been reported yet. In this study, we assessed intestinal FGF19 production and the hepatic response to FGF19 in NAFLD patients with and without insulin resis...

30 Intestinal FGF19 has emerged as a novel endocrine regulator of hepatic bile salt and lipid 31 metabolism. In patients with non-alcoholic fatty liver disease (NAFLD) hepatic lipid 32 metabolism is deranged. A possible role of FGF19 in NAFLD has not been reported yet. In this 33 study, we assessed intestinal FGF19 production and the hepatic response to FGF19 in NAFLD 34 patients with and witho...

BACKGROUND AND AIMS We aimed to study the prevalence and the predictive factors of non-alcoholic fatty liver disease (NAFLD) defined by the fatty liver index (FLI) in type 2 diabetic patients (T2DM). METHODS Three hundred and eighty-one T2DM outpatients who regularly attended a Consulting Clinic in Cluj were retrospectivelly included. FLI, a surrogate steatosis biomarker based on body mass in...

Nonalcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease, is increased worldwide in parallel with the obesity epidemic. Our previous studies have showed that the extract of I. hainanensis (EIH) can prevent NAFLD in rat fed with high-fat diet. In this work, we aimed to find biomarkers of NAFLD and investigate the therapeutic effects of EIH. NAFLD model was induced ...

Transforming growth factor beta 3 (TGFb3) was mainly expressed by liver satellite cells in the normal liver, but it may be expressed by various liver cells during liver diseases, e.g. hepatitis and cirrhosis. However, whether TGFb3 level may be used to predict development of nonalcoholic fatty liver disease (NAFLD) has not been investigated before. Here we evaluated the relationship between TGF...

Association between non-alcoholic fatty liver disease (NAFLD) and various cardiovascular diseases has been demonstrated previously. Recent clinical studies have shown that increased circulating levels of γ glutamyl transpeptidase and liver transaminase, markers which are elevated in NAFLD, increase the risk of new-onset atrial fibrillation. We conducted a systematic review and meta-analysis of ...